Form 4: MPM BioVentures Sells Werewolf Therapeutics Shares

MPM BioVentures, a 10% owner and director, reported the sale of over 213,000 shares of Werewolf Therapeutics common stock through a pre-arranged 10b5-1 plan.

Summary

• MPM BioVentures 2014, L.P., a 10% owner and director of Werewolf Therapeutics, Inc. (HOWL), reported multiple sales of common stock.
• A total of 213,529 shares were sold across four transactions between November 7, 2025, and November 12, 2025.
• The sales were executed under a Rule 10b5-1 trading plan established on September 24, 2025.
• On November 7, 2025, 68,480 shares were sold at a weighted average price of $1.11, leaving 5,836,240 shares beneficially owned.
• On November 10, 2025, 48,570 shares were sold at a weighted average price of $1.18, leaving 5,787,670 shares beneficially owned.
• On November 11, 2025, 55,810 shares were sold at a weighted average price of $1.14, leaving 5,731,860 shares beneficially owned.
• On November 12, 2025, 40,669 shares were sold at a weighted average price of $1.09, leaving 5,691,191 shares beneficially owned.
• The shares were sold by various affiliated entities including MPM Asset Management LLC, MPM BioVentures 2014, L.P., MPM BioVentures 2014(B), L.P., MPM Asset Management Investors BV2014 LLC, MPM Oncology Innovations Fund, L.P., and UBS Oncology Impact Fund L.P.

Sentiment

Score: 3

Explanation: The sale of a substantial number of shares by a 10% owner and director, MPM BioVentures, is typically viewed as a negative indicator for the stock. While the transactions were executed under a Rule 10b5-1 plan, which suggests a pre-determined divestment strategy rather than a reaction to new adverse information, it still represents a reduction in a major holder's stake.

Positives

• The sales were conducted under a pre-arranged Rule 10b5-1 plan, indicating a planned divestment rather than an immediate reaction to new information.
• The selling entity realized proceeds from the sale of shares.

Negatives

• A significant 10% owner and director entity sold a substantial number of shares (213,529 shares).
• Insider selling can be perceived negatively by the market, potentially signaling a lack of confidence or a belief that the stock price may not appreciate significantly in the near term.
• The sales occurred at relatively low price points, ranging from $1.09 to $1.18 per share.

Future Outlook

NA

Industry Context

This filing reflects a routine insider transaction by a significant institutional investor in a biotechnology company. Such sales are common for venture capital or private equity firms as they manage their portfolio liquidity and return capital to limited partners, especially as companies mature or after an IPO. The specific impact on Werewolf Therapeutics depends on market perception and the broader context of the company's clinical and financial progress.

Stakeholder Impact

• Shareholders: May interpret the insider selling as a negative signal, potentially leading to downward pressure on the stock price.
• Company Management: The sales by a significant investor could prompt questions about the company's near-term prospects or valuation from other investors.

Key Dates

Recommendation

The sale of over 213,000 shares by a 10% owner and director, MPM BioVentures, is a notable event. While executed under a Rule 10b5-1 plan, which implies a pre-scheduled divestment, it still represents a reduction in a significant institutional stake. This action, particularly at the reported price levels, suggests that this major investor may not anticipate substantial near-term upside. For existing investors, holding the stock while monitoring company performance and future insider activity is prudent. For prospective investors, this insider selling warrants caution and further due diligence into Werewolf Therapeutics' fundamentals and pipeline before initiating a position.

Keywords

Werewolf Therapeutics, HOWL, SEC Form 4, insider selling, MPM BioVentures, 10b5-1 plan, common stock, beneficial ownership, institutional investor, biotechnology, pharmaceutical